Ellen De Roeck
University of Antwerp
4 Papers
13 Citations
Ellen De Roeck is an academic researcher from University of Antwerp. The author has contributed to research in topics: Dementia & Medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.
Julie Ottoy,Ellis Niemantsverdriet,Jeroen Verhaeghe,Ellen De Roeck,Hanne Struyfs,Charisse Somers,Leonie Wyffels,Sarah Ceyssens,Sara Van Mossevelde,Tobi Van den Bossche,Christine Van Broeckhoven,Annemie Ribbens,Maria Bjerke,Sigrid Stroobants,Sebastiaan Engelborghs,Steven Staelens +15 more
TL;DR: Neither amyloid-PET nor CSF biomarkers could discriminate short-term converters from non-converters, and patients with MCI converted to AD dementia at an annual rate of 31%, which could be best predicted by combining neuropsychological testing with either MRI-based HV or 18F-FDG-PET.
136
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
Min Kim,Stuart G. Snowden,Tommi Suvitaival,Adnan Ali,David J. Merkler,Tahmina Ahmad,Sarah Westwood,Alison L. Baird,Petra Proitsi,Alejo J. Nevado-Holgado,Abdul Hye,Isabelle Bos,Stephanie J.B. Vos,Rik Vandenberghe,Charlotte E. Teunissen,Mara ten Kate,Philip Scheltens,Silvy Gabel,Karen Meersmans,Olivier Blin,Jill C. Richardson,Ellen De Roeck,Kristel Sleegers,Régis Bordet,Lorena Rami,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Isabel Sala,Alberto Lleó,Gwendoline Peyratout,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Sebastiaan Engelborghs,Giovanni B. Frisoni,José Luis Molinuevo,Anders Wallin,Julius Popp,Pablo Martinez-Lage,Lars Bertram,Frederik Barkhof,Nicholas J. Ashton,Kaj Blennow,Henrik Zetterberg,Johannes Streffer,Pieter Jelle Visser,Simon Lovestone,Cristina Legido-Quigley +50 more
TL;DR: This data indicates that metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers may be linked to brain pathology in patients with AD.
Replication study of plasma proteins relating to Alzheimer's pathology
Liu Shi,Laura Winchester,Sarah Westwood,Alison L. Baird,Sneha N Anand,Noel J. Buckley,Abdul Hye,Nicholas J. Ashton,Nicholas J. Ashton,Isabelle Bos,Isabelle Bos,Stephanie J.B. Vos,Mara ten Kate,Philip Scheltens,Charlotte E. Teunissen,Rik Vandenberghe,Silvy Gabel,Karen Meersmans,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Ellen De Roeck,Kristel Sleegers,Giovanni B. Frisoni,Olivier Blin,Jill C. Richardson,Régis Bordet,José Luis Molinuevo,Lorena Rami,Anders Wallin,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Alberto Lleó,Isabel Sala,Julius Popp,Julius Popp,Gwendoline Peyratout,Pablo Martinez-Lage,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Cristina Legido-Quigley,Cristina Legido-Quigley,Frederik Barkhof,Ulf Andreasson,Ulf Andreasson,Kaj Blennow,Kaj Blennow,Henrik Zetterberg,Johannes Streffer,Christina M. Lill,Christina M. Lill,Lars Bertram,Lars Bertram,Pieter Jelle Visser,Pieter Jelle Visser,Hartmuth C. Kolb,Vaibhav A. Narayan,Simon Lovestone,Simon Lovestone,Alejo J. Nevado-Holgado +63 more
TL;DR: In this paper, the authors sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the "ATN" (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis.
16
18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O-H2O PET
Julie Ottoy,Jeroen Verhaeghe,Ellis Niemantsverdriet,Ellen De Roeck,Leonie Wyffels,Sarah Ceyssens,Christine Van Broeckhoven,Sebastiaan Engelborghs,Sigrid Stroobants,Steven Staelens +9 more
TL;DR: The perfusion components of early‐phase 18F‐florbetapir (eAV45), the18F‐AV45 delivery rate (R1), and 18F-FDG against 15O‐H2O PET and assess how they change with disease severity are validated.